1 | the standard for cannabinoid | | | | | | | 2 | 0.75% |
2 | to learn more about | | | | | | | 2 | 0.75% |
3 | next steps next steps | | | | | | | 2 | 0.75% |
4 | your next steps next | | | | | | | 2 | 0.75% |
5 | about your next steps | | | | | | | 2 | 0.75% |
6 | more about your next | | | | | | | 2 | 0.75% |
7 | learn more about your | | | | | | | 2 | 0.75% |
8 | here to learn more | | | | | | | 2 | 0.75% |
9 | standard for cannabinoid therapy | | | | | | | 2 | 0.75% |
10 | click here to learn | | | | | | | 2 | 0.75% |
11 | medical authorization if you | | | | | | | 2 | 0.75% |
12 | across 60000 patient engagements | | | | | | | 1 | 0.37% |
13 | of medical healthcare professionals | | | | | | | 1 | 0.37% |
14 | hundreds of medical healthcare | | | | | | | 1 | 0.37% |
15 | of hundreds of medical | | | | | | | 1 | 0.37% |
16 | experiences of hundreds of | | | | | | | 1 | 0.37% |
17 | 60000 patient engagements and | | | | | | | 1 | 0.37% |
18 | skip to content canabo | | | | | | | 1 | 0.37% |
19 | patient engagements and insights | | | | | | | 1 | 0.37% |
20 | engagements and insights from | | | | | | | 1 | 0.37% |
21 | and insights from the | | | | | | | 1 | 0.37% |
22 | insights from the 10000000 | | | | | | | 1 | 0.37% |
23 | medical patient data points | | | | | | | 1 | 0.37% |
24 | patient data points we’ve | | | | | | | 1 | 0.37% |
25 | data points we’ve collected | | | | | | | 1 | 0.37% |
26 | points we’ve collected to | | | | | | | 1 | 0.37% |
27 | we’ve collected to create | | | | | | | 1 | 0.37% |
28 | collected to create bestinclass | | | | | | | 1 | 0.37% |
29 | processes and support systems | | | | | | | 1 | 0.37% |
30 | and support systems for | | | | | | | 1 | 0.37% |
31 | support systems for all | | | | | | | 1 | 0.37% |
32 | systems for all cannabinoid | | | | | | | 1 | 0.37% |
33 | therapy experiences of hundreds | | | | | | | 1 | 0.37% |
34 | therapy we have leveraged | | | | | | | 1 | 0.37% |
35 | the combined applied cannabinoid | | | | | | | 1 | 0.37% |
36 | for patient’s as we | | | | | | | 1 | 0.37% |
37 | approach allows us to | | | | | | | 1 | 0.37% |
38 | allows us to efficiently | | | | | | | 1 | 0.37% |
39 | us to efficiently scale | | | | | | | 1 | 0.37% |
40 | to efficiently scale our | | | | | | | 1 | 0.37% |